Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more
Abionyx Pharma SA - Asset Resilience Ratio
Abionyx Pharma SA (ABNX) has an Asset Resilience Ratio of 26.08% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Abionyx Pharma SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Abionyx Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.87 Million | 26.08% |
| Total Liquid Assets | €3.87 Million | 26.08% |
Asset Resilience Insights
- Very High Liquidity: Abionyx Pharma SA maintains exceptional liquid asset reserves at 26.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abionyx Pharma SA Industry Peers by Asset Resilience Ratio
Compare Abionyx Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Abionyx Pharma SA (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Abionyx Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.34% | €50.00K | €14.83 Million | +0.60pp |
| 2022-12-31 | -0.26% | €-41.00K | €15.82 Million | -0.12pp |
| 2021-12-31 | -0.14% | €-31.00K | €21.83 Million | -- |
| 2020-12-31 | 0.00% | €0.00 | €10.29 Million | -- |
| 2019-12-31 | 73.85% | €7.57 Million | €10.25 Million | +1.56pp |
| 2018-12-31 | 72.30% | €9.50 Million | €13.13 Million | +7.90pp |
| 2016-12-31 | 64.39% | €18.72 Million | €29.07 Million | -- |